Microglia-Mediated Neuroprotection, TREM2, and Alzheimer's Disease: Evidence From Optical Imaging

Carlo Condello1, Peng Yuan2, Jaime Grutzendler3

  • 1Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California; Department of Neurology, University of California, San Francisco, San Francisco, California.

Biological Psychiatry
|November 25, 2017
PubMed

Insights

Microglia protect the brain in Alzheimer's disease (AD) by forming a barrier around amyloid plaques. Defective barriers, linked to TREM2 variants, worsen AD pathology and axonal damage.

Area of Science:

  • Neuroscience
  • Immunology

Background:

  • Microglia, the brain's immune cells, are increasingly implicated in Alzheimer's disease (AD) pathophysiology.
  • The exact mechanisms by which microglia influence AD progression are not fully understood.

Purpose of the Study:

  • To explore the neuroprotective roles of microglia in AD.
  • To highlight the "microglia barrier" function in encapsulating amyloid deposits.
  • To investigate the link between TREM2 variants, microglia function, and AD risk.

Main Methods:

  • Review of optical imaging studies on microglia-amyloid interactions.
  • Discussion of genetic evidence linking TREM2 variants to late-onset AD.
  • Analysis of microglia polarization and its impact on plaque pathology.

Main Results:

  • Microglia form a "barrier" that compacts amyloid plaques and protects axons, reducing neurotoxicity.
  • Genetic variants in TREM2 are associated with increased AD risk.
  • Deficient microglia polarization leads to ineffective plaque encapsulation and axonal damage.

Conclusions:

  • The microglia barrier is a key neuroprotective mechanism in AD.
  • Dysfunctional microglia, potentially due to TREM2 variants, contribute to AD progression.
  • Therapeutic strategies targeting microglia may offer a way to enhance the barrier and slow disease progression.